As shown in Figure 6A–D, CHRNA9 knockdown induced a significant reduction in tumor volumes and tumor weights compared to the control group, which suggested α9 nAChR should be a useful therapeutic target for TNBC. Here, CHRNA9 is linked to neoplasm.